Yu no bɔt HER2-Negative Breast Cancer? Mek wi tok!

Yu go mɔs dɔn yɛri bɔku tin bɔt bɔdi kansa. Bɔt yu rili no wetin dɛn kɔl dis kayn kansa ‘HER2-negative’? I kin biev smɔl difrɛn frɔm sɔm ɔda kayn bɔdi kansa, ɛn di tritmɛnt kin difrɛn. Nɔ wɔri, tide wi go tɔk bɔt dis `HER2-Negative Breast Cancer` insay wan simpul we we yu go ɔndastand, okay?

Wetin na HER2-Negative Breast Cancer?

fכ simpul wan, `HER2-nεgεtiv brεst kεnsar` min se di kεnsar sεl dεm na yu brεst nכ gεt tu mכch כ tu sכm spεshal protin we dεn kכl `human epidermal growth factor 2 (HER2). yu no se brεst kεnsar kin kכmכt biכs fכ di כmon dεm (especially estrogen εn projesterone) כ bikoz fכ dis `HER2` protin? fכ egzampl, insay `HER2-positiv` brεst kεnsar, di `HER2` protin de na di sεl dεm we de fכm, we de mek di kεnsar sεl dεm divayd kwik kwik wan εn fכm tכmכro.

bכt insay `HER2-nεgεtiv` kes dεm, di kεnsar nכ de divεlכp biכs i tu mכch `HER2` protin de. Dat min se ɔda tin dɛn de insay dis.

We yu dɔktɔ no se yu gɛt brɔst kansa, dɛn go mɔs luk fɔ yu `HER2` stetɔs (i.e., pɔsitiv ɔ nɛgitiv). dis na di spεshal kכntribyushכn dεm fכ di kεnsar sεl dεm, we wi kכl `biomarkers` , εn we dεn כndastand dεm kכrekt wan, dכkta dεm kin disayd us tritmεnt we fit εn ifektiv fכ yu. Dɔn gɛt am?

Wetin na di men kayn HER2-negativ brɔst kansa?

di mכtalman in bכdi kεnsar dεm we dεn de no naw na di `HER2-negative` tכp. Tu men kayn dis de, lɛ wi tek wan luk pan wetin dɛn bi:

1. כmon rεsεptכr-positiv εn HER2-nεgεtiv brεst kεnsar (HR+/HER2-) :

Dis na di kayn brɔst kansa we bɔku pipul dɛn kin gɛt, we kin mek lɛk 70 pasɛnt (70%) pan ɔl di bɔdi kansa dɛn. insay dis kes, di kansa sεl dεm gεt rεsεpכta dεm we de sεnsitiv to εstrojen כmon (ER+), di prכjestεron כmon (PR+), כ כl tu. Fɔ tɔk am simpul wan, we dɛn ɔmon ya tay pan dɛn riseptɔ dɛn ya, di kansa sɛl dɛn kin bigin fɔ gro. כltu, dεn kayn kεnsar dεm ya nכ gεt hכy lεvεl fכ di HER2 protin. Na dat mek dɛn kɔl dɛn HR+/HER2-.

2. כmon rεsεpכta-nεgεtiv εn HER2-nεgεtiv brεst kεnsar (HR-/HER2-) :

dis kayn we de mek lεk 11 pasεnt (11%) pan כl di brεst kεnsar dεm. dis kεnsar sεl dεm nכ gεt rεsεpכta fכ εstrojen כ prכjεstεron. כlso, lεk aw wi bin dכn tכk, di `HER2` protin nכ hכy. dis min se nכ כmon dεm nכ di `HER2` protin de kכntribyut fכ mek dis kεnsar gro . Wan ɔda nem fɔ dis na `Triple-Negative Breast Cancer` . dis na biכs di εstrojen rεsεpכta, projεstεron rεsεpכta, εn `HER2` protin כl na `nεgεtiv` insay dis kes.

Wetin na di simptom dɛm fɔ HER2-negative breast cancer?

infakt, di simptom dεm fכ HER2-negative brεst kεnsar rili fiba di wan dεm fכ εni כda brεst kεnsar. Yu fɔ no bɔt dɛn tin ya:

• If yu notis wan chenj we nɔ kɔmɔn na di sayz ɔ shep fɔ wan ɔ ɔl tu yu bɔdi.
• If yu notis nyu lump, lump, ɔ tayt na yu brɔst ɔ armpit, mɔ if di lump nɔ chenj wit yu mɔnt saikl.
• di chenj dεm we de apin na di skin na di brεst כ di nipl. Fɔ ɛgzampul:
• Dimpling na di skin, lɛk ɔrɛnj peel
• Skin de rɔtin, we de rɔtin
• Skin we gɛt skel
• Wan it we pɔsin kin it ɔltɛm
• Skin kɔlɔ kin chenj (rɛd, pepul, brawn, ɔ dak we nɔ kɔmɔn).
• Di wata we de kɔmɔt na di nipple . Dis kin bi rɛd lɛk blɔd, klia wata, ɔ wayt kɔlɔ we tan lɛk milk (if yu nɔ gɛt bɛlɛ ɔ yu de gi pikin bɔbi).
• Nipple inversion (if i nɔ bin de bifo).

I impɔtant fɔ no se nɔto ɔltɛm yu bɔdi kansa kin mek yu chenj klia wan na di we aw yu luk . כlso, yu kin si bכku pan dεn chenj dεm ya bak pan benign, nכmal kכndishכn dεm (e.g. sist, fibroadenoma). Na dat mek i rili impɔtant fɔ de wach yu bɔdi ɔltɛm ɛn gɛt fɔ chɛk yu bɔdi kansa we fit yu ej . If yu gɛt ɛnitin we de mɔna yu bɔt chenj, mek shɔ se yu go to dɔktɔ fɔ no if na sayn fɔ kansa ɔ ɔda sik.

Wetin kin mek yu gɛt HER2-negativ brɔst kansa?

Fɔ tɔk am simpul wan, HER2-negativ brɔst kansa kin kɔmɔt frɔm di chenj dɛn we de apin na di jin ɔ DNA na di bɔdi sɛl dɛn, we dɛn kɔl mutations , we kin mek dɛn sɛl dɛn de bi kansa sɛl. Dɔn dɛn kansa sɛl ya kin sheb ɛn bɔku kwik kwik wan we dɛn nɔ kin kɔntrol, ɛn dɛn kin mek tɔŋ dɛn.

Tin dɛn we kin mek pɔsin gɛt prɔblɛm

di masta sabi pipul dεm stil nכ no fכ sכri wetin di εksakכt kכz fכ dεn jεnεtik mכtεshכn ya na HER2-nεgεtiv brεst kεnsar dεm. Bɔt dɛn dɔn no bɔku tin dɛn we kin mek pɔsin gɛt mɔ kansa na in bɔdi. Dɛn tin ya na:

• inhεrit jεnεtik mכtεshכn : nכ spεsifi k jεnεtik mכtεshכn de we de sho se i gεt HER2-rεlatεd brεst kεnsar. כltu, if pכsin inhεrit wan mכtεshכn in jin dεm lεk BRCA1 כ BRCA2, dεn de pan hכy risk fכ gεt brεst kεnsar (εn sכm כda kεnsar dεm) in jεnarכl.
• Yu ɔ sɔmbɔdi na yu famili dɔn gɛt bɔdi kansa bifo.: If yu dɔn gɛt bɔdi kansa bifo, yu gɛt sɔm risk fɔ mek i kam bak. Dɔn bak, if yu fambul dɛn we yu blɔd (espɛshali yu mama, papa, brɔda ɛn sista dɛn, pikin dɛn) dɔn gɛt bɔdi kansa, yusɛf gɛt di risk smɔl.
• Lכng tεm we yu de yuz εstrojen כ projεstεron כmon : If yu bigin yu fכs pεriכd we yu yכng (e.g., bifo yu ol 12 ia), כ if yu bin de let mεnopos (e.g., afta yu ol 55 ia), yu bכdi dεn bin de εkspos to dεn sεks כmon dεm ya fכ lכng tεm. Dis kin bi bak wan risk factor. Sɔm ɔmon riplesmɛnt tritmɛnt dɛn kin mek yu gɛt mɔ prɔblɛm bak we dɛn tek am fɔ lɔng tɛm.
• Yuz rɔm : Risach dɔn sho se if yu drink pas wan standad drink fɔ wan de, dat kin mek yu gɛt kansa na yu bɔdi bak.

Apat frɔm dis, tin dɛn lɛk we pɔsin de ol, we i fat, ɛn we i nɔ de du ɛksɛsayz kin mek bak di risk fɔ gɛt bɔdi kansa insay jɔnaral.

Aw dɛn kin no HER2-negativ brɔst kansa?

Dɔktɔ dɛn kin no se i gɛt HER2-negative breast cancer tru wan breast biopsy . Dis involv fɔ tek wan smɔl sampul (pies) pan di tisu frɔm wan lump ɔ eria we yu tink se ɛn sɛn am to lab. Na de, wan dɔktɔ we de stɔdi bɔt sik dɛn kin chɛk di sampul ɔnda maykroskɔp fɔ si if kansa sɛl dɛn de.

if dεn kכnfכm di kεnsar sεl dεm, dεn kin du spεshal tεst dεm fכ si כl di `HER2` protin de na di sεf fכ dεn kεnsar sεl dεm, כ כl di kכpi dεm fכ di `HER2` jin de.

• if yu gεt nכmal (lכw) amoun dεm fכ di `HER2` protin כ jin, yu gεt `HER2-nεgεtiv` brεst kεnsar.

Di tu men laboratori tɛst dɛm we dɛn kin du fɔ dis na:

1. Immunohistochemistry (IHC) : Dis tεst de yuz spεsifi k antibodi dεm εn day fכ no di HER2 protin we de na di sεf fכ di kεnsar sεl dεm. if di IHC rizulεt na 0 כ 1+, dεn kin kכnsidr di kεnsar as HER2-nεgεtiv. if di risal na 2+ (sכmtεm dεn kin kכl am "equivocal" כ "borderline"), dεn kin du wan tεst we dεn kכl FISH bak fכ kכnfכm di HER2 stetכs.

2. Fluorescence in situ hybridization (FISH) : dis tεst de luk aw כl di kכpi dεm fכ di HER2 jin, we de mek di HER2 protin, de insay kεnsar sεl dεm. Dis de yuz spɛshal maykroskɔp ɛn fluorescent (layt-emitting) mak dɛn. insay kes dεm we di IHC tεst risכlt nכ kכnklud, lεk 2+, di FISH tεst kin dεfinitivli kכnfכm di HER2 stetכs (nεgεtiv כ positifu).

apat frכm dεn `HER2` tεst dεm ya, di patכlayz go egzamin di bayopsi sεmpl bak εn luk fכ di prεsεns fכ εstrojen rεsεpכta dεm (ETU) εn projεstεron rεsεpכta dεm (PR) insay di kεnsar.

Yu kin nid bak fɔ gɛt imej prosidur lɛk mamogram, ɔltra saund, CT skan, ɔ MRI skan fɔ no di stej we yu kansa gɛt (dat na fɔ si aw di tumbu big ɛn if i dɔn spre to limf no dɛm ɔ ɔda pat dɛm we de fa na di bɔdi).

Yu dɔktɔ go jɔyn ɔl dis infɔmeshɔn (HER2 stetɔs, HR stetɔs, kansa stej, ɛn kansa kwaliti dɛm) fɔ mek di tritmɛnt plan we fit yu pas ɔl.

Wetin na di tritmɛnt dɛm fɔ HER2-negativ brɔst kansa?

Di bɛst tritmɛnt fɔ HER2-negativ brɔst kansa kin difrɛn frɔm wan pɔsin to ɔda pɔsin. I dipen pan bɔku tin dɛm, lɛk di stej we yu kansa gɛt, if na ɔmon riseptɔ-pɔzitiv ɔ nɛgitiv (HR+/HER2- ɔ HR-/HER2-), ɛn yu ɔl wɛl bɔdi.

Jɛnɛral wan, di tritmɛnt dɛn kin inklud:

• Breast cancer surgery : Na we dɛn kin pul di kansa tɔŋ ɛn sɔntɛm sɔm wɛlbɔdi tisu dɛn we de rawnd am. dis kin bi lumpectomy, we de pul wan pat pan di brεst, כ mastectomy, we de pul di wan ol brεst.
• Radiation therapy : Dɛn kin yuz ay ɛnaji rayt fɔ pwɛl ɛni kansa sɛl we kin lɛf afta dɛn du di ɔpreshɔn, ɔ fɔ mek di tumbu smɔl bifo dɛn du di ɔpreshɔn.

Apat frɔm dɛn bɛsis tritmɛnt ya, ɔda patikyula tritmɛnt dɛn de we dipen pan di kayn kansa:

Tritmεnt fכ HR+/HER2- (hכmon rεsεptכr-positiv, HER2-nεgεtiv) brεst kεnsar

Bikɔs dis kayn kansa de dipen pan ɔmon, dɛn tritmɛnt ya impɔtant bak apat frɔm ɔpreshɔn ɛn/ɔ redyushɔn tɛrapi:

• Ɔmon tɛrapi : Dɛn tritmɛnt ya de wok bay we dɛn de ridyus di ɔmon dɛn we dɛn kɔl ɛstrojen ɔ prɔjɛstɛron we de ɛp kansa fɔ gro, ɔ bay we dɛn de stɔp dɛn ɔmon dɛn de fɔ tay pan di kansa sɛl dɛn. Fɔ ɛgzampul:
• Aromatase inhibito dεm (e.g. Anastrozol, Lεtrozol, Exemestane) .
• di gonadotropin-rilis כmon (GnRH) agonist dεm (stכp di prodyushכn כmon dεm frכm di ovaria dεm) .
• `Sεlektiv εstrojen rεsεptכr mכdulet dεm (SERM)` (e.g. Tamoxifen, Raloxifene)

Sɔntɛnde, yu kin nid fɔ du ɔpreshɔn (oophorectomy) fɔ pul yu ovaries, we de mek ɛstrojen. Dɛn kin gi ɔmon tritmɛnt in wan ɔ dɛn kin gi am togɛda wit tritmɛnt we dɛn dɔn tɔk bɔt fɔ sɔm ia.

• Targeted therapy : Dɛn tritmɛnt ya de tɔch sɔm patikyula wikɛd tin dɛm na di kansa sɛl dɛm ɛn atak dɛm fɔ stɔp di growth ɛn spred fɔ di kansa sɛl dɛm. fכ HR+/HER2- kεnsar, dεn de yuz dεm we dεn kכl CDK4/6 inhibito dεm (e.g. Palbociclib, Ribociclib, Abemaciclib) we dεn kכmbayn wit כmon tεrapi. dis dεm de blכk wan εnzym we de kכntro di divεlכpmεnt fכ di kεnsar sεl dεm.
• Kimotɛrapi: Fɔ sɔm HR+/HER2- brɔst kansa, mɔ if di kansa dɔn skata ɔ i de agresiv, dɔktɔ dɛn kin tɛl yu fɔ tek kimotɛrapi wit ɔmon tɛrapi ɛn/ɔ tritmɛnt we dɛn want fɔ tek.

Tritmɛnt fɔ HR-/HER2- (tripul-nɛgitiv) brɔst kansa

Bikɔs triplɛ-nɛgitiv brɔst kansa nɔ de dipen pan ɔmon, ɔmon tɛrapi nɔ de wok. Apat frɔm ɔpreshɔn ɛn/ɔ redyushɔn tɛrapi, dɛn kin yuz dɛn tritmɛnt ya mɔ:

• Kimotɛrapi : Kimotɛrapi na rili impɔtant tritmɛnt fɔ triplɛ-nɛgitiv kansa. Dɔktɔ dɛn kin yuz difrɛn kayn kemotɛrapi mɛrɛsin dɛn. Dɛn kin gi wan mɛrɛsin ɔ sɔm mɛrɛsin dɛn we dɛn jɔyn togɛda.
• Immunotherapy : Dis na nyu tritmɛnt. I de wok bay we i de mek yu bɔdi in yon imyun sistɛm no ɛn pwɛl di kansa sɛl dɛn. Pembrolizumab (Keytruda®) na wan imyunotɛrapi drɔg we di Food and Drug Administration (FDA) dɔn gri fɔ ɛn dɛn kin gi am wit kemotɛrapi fɔ sɔm kayn tripl-nɛgitiv brɔst kansa.
• Tagεt tεrapi : Fכ tripl-nεgεtiv kεnsar wit BRCA jin mכtεshכn, dεn de yuz tכgεt dεm we dεn kכl PARP inhibito dεm (e.g., Olaparib, Talazoparib). כlso, fכ mεtastas sik, nyu kayn tεrapi dεm we dεn tכk bכt (e.g., antibodi-drug kכnjugεt) dεn de naw.

Wetin na di sayd ɛfɛkt dɛm we di tritmɛnt dɛm kin gɛt?

Pan ɔl we di tritmɛnt fɔ kansa kin ebul fɔ fɛt kansa fayn fayn wan, ɔl di tritmɛnt dɛn, lɛk kemotɛrapi, redyushɔn tɛrapi, ɔmon tɛrapi, targeted therapy, ɛn immunotherapy, kin mek sɔm bad bad tin dɛn apin. Dɛn tin ya kin bi fɔ sɔm tɛm ɔ fɔ lɔng tɛm. Fɔ ɛgzampul, taya, nɔs, vɔmit, ia we de lɔs, nɔ want fɔ it, yu mɔt de sɔfa, yu skin de chenj, yu gɛt dayarɛa ɔ yu gɛt kɔnstipɛshɔn, ɛn yu blɔd sɛl nɔ de bɔku.

Mek shɔ se yu tɔk to yu dɔktɔ bɔt wetin na dɛn sayd ɛfɛkt ya, aw lɔng dɛn go las, ɛn aw fɔ mɛn dɛn. Dɛn kin rifer yu bak to palliativ kia spɛshal pipul dɛn. Palliative care nɔto jɔs fɔ di las stej dɛm fɔ kansa, bɔt i de ɛp yu bak fɔ kip yu kwaliti layf bay we yu de manej di simptom ɛn sayd ɛfɛkt dɛm ɔlsay na di tritmɛnt.

Wetin na di kɔrej rit fɔ HER2-nɛgitiv brɔst kansa?

insay כl di HER2-nεgεtiv brεst kεnsar dεm, di rεt we di kεnsar de kכnfyus na di brεst εn i nכ spre (lכkal stej) pas we di kεnsar dכn spre to di fa fa כgan dεm na di bכdi (e.g., liva, lכng, bren, bon) (mεtastatik kεnsar כ distant stej).di rεt fכ sכvayv fכ kεnsar dεm we dεn spre כnli to di limf no dεm we de nia bכt we nכ spre to di כgan dεm we de fa (rijכnal stej) de sכmsay bitwin.

Bɔt i impɔtant fɔ mɛmba se di chans fɔ mek yu wɛl, ɔr di prɔgnosis, dipen pan tin dɛm wae gɛt fɔ du wit yu diagnosis. Dɛn tin ya na aw fa di kansa dɔn skata (stej), if di kansa gɛt ɔmon riseptɔ stetɔs (HR+/HER2- ɔ HR-/HER2-), aw di kansa sɛl dɛn agresiv (grɛd), yu ej, ɔl yu wɛlbɔdi, ɛn aw yu de ansa to tritmɛnt. Dis na tin dɛm wae yu dɔktɔ kin tɔk to yu bɔt ɛn ɛksplen to yu wetin fɔ ɛkspɛkt. Statistikin na jɔs avrej, ɛn i nɔ go bi di sem fɔ ɔlman.

Aw a kin kia fɔ misɛf? (Fɔ kia fɔ yusɛf) .

If yu na pɔrsin wae gɛt HER2-negativ brɔst kansa wae de bigin ɔr pɔrsin wae de liv wit advans kansa, i impɔtant fɔ tek tɛm fɔ kia fɔ yusɛf. Dis go ɛp yu pan yu bɔdi ɛn yu maynd. Na sɔm tin dɛn we yu kin du:

• Rɛst we yu nid fɔ : I nɔmal fɔ fil taya ɛn taya, ɔl tu frɔm kansa ɛn kansa tritmɛnt. We yu fil taya, tek smɔl tɛm fɔ blo ɛn rɛst. Lisin to yu bɔdi.
• It fayn it we gɛt fayn fayn tin dɛn fɔ it : Sɔm tritmɛnt dɛn fɔ kansa kin afɛkt di we aw yu want fɔ it ɛn di we aw yu de teist. Bɔt tray fɔ it tin dɛn we go mek yu gɛt di tin dɛn we yu bɔdi nid. Put frut, vɛjitebul, fayv, ɛn it dɛn we gɛt bɔku prɔtin. If yu nɔ shɔ bɔt us it fɔ it ɛn wetin nɔ fɔ it, tɔk to pɔsin we sabi bɔt it fɔ advays.
• Ɛksesaiz (bɔt nɔ fɔ du am pasmak) : I impɔtant fɔ du ɛksɛsayz ɔltɛm na di lɛvul we rayt fɔ yu, lɛk aw yu dɔktɔ tɛl yu. Ivin fɔ waka layt ɔ fɔ du yoga kin fayn. I kin mek yu gɛt mɔ trɛnk, mek yu fil fayn, ɛn ɛp fɔ ridyus di bad tin dɛn we kin apin to yu. Bɔt aks yu dɔktɔ us kayn ɛksesaiz we fayn fɔ yu ɛn ɔmɔs yu fɔ du, bay aw yu dɔn no bɔt di sik ɛn aw yu de trit yu.
• Manej strɛs : Na nɔmal tin fɔ fil strɛs, wɔri, ɛn frayd wit sik lɛk dis. Fɛn we dɛn fɔ manej am we go wok fɔ yu. Pan ɔl we fɔ tink gud wan ɛn fɔ blo fayn fɔ sɔm pipul dɛn, ɔda pipul dɛn kin lɛk fɔ du tin dɛn we dɛn kin mek lɛk fɔ rid buk, lisin to myuzik, fɔ drɔ, ɔ fɔ mek gadin. Put sɔm tɛm ɛvride fɔ ɛnitin we go ɛp yu fɔ fil kol ɛn rilaks.
• Gɛt saykolojik sɔpɔt: I impɔtant fɔ tɔk bɔt aw yu de fil wit yu fambul ɛn yu tayt padi dɛn. I kin rili ɛp bak fɔ kɔnɛkt wit ɔda pipul dɛm wae de dil wit kansa diagnosis ɛn sheb dɛn ɛkspiriɛns. Aks yu dɔktɔ bɔt sɔpɔt grup ɔr program fɔ sev frɔm kansa.

Ustɛm a fɔ go to di dɔktɔ?

I rili impɔtant fɔ mek yu kɔntinyu fɔ tɔk to yu dɔktɔ ɔltɛm, we yu de du tritmɛnt ɛn afta yu dɔn trit yu.

• If yu gɛt nyu sayn dɛm (e.g., pen we de kɔntinyu, nyu lump, i nɔ izi fɔ blo, yu de lɔs yu wet we yu nɔ ebul fɔ ɛksplen), ɔ if i tan lɛk se di sik we yu gɛt naw de wɔs , go ɔ tɛl yu dɔktɔ wantɛm wantɛm .
• Afta yu dɔn gɛt tritmɛnt, yu dɔktɔ go sɛtul fɔ mek dɛn go fala yu ɔltɛm . Mek shɔ se yu kip dɛn apɔntin dɛn ya. Dɛn tin ya na fɔ chɛk fɔ si if i de kam bak, fɔ manej di lɔng tɛm sayd ɛfɛkt dɛm we di tritmɛnt gɛt, ɛn fɔ chɛk yu ɔl wɛl bɔdi. Dɛn fɔlɔp apɔntin ya impɔtant mɔ insay di fɔs fayv ia afta dɛn dɔn trit am . Dis na di tɛm we kansa kin kam bak bɔku tɛm.

Us kwɛstyɔn dɛn a fɔ aks mi dɔktɔ?

We yu de tɔk to yu dɔktɔ, nɔ fred fɔ aks ɛni kwɛstyɔn we yu gɛt, ilɛksɛf i smɔl. Na sɔm kwɛstyɔn dɛn we yu kin aks fɔ ɛp yu:

• Mi kansa ɔmon riseptɔ-positiv ɔ negatif?
• Wetin na di patikyula sɔbtayp ɛn stej fɔ mi kansa?
• Us tritmɛnt yu kin kɔmɛnt fɔ mi? Wetin du?
• Wetin na di shɔt tɛm ɛn lɔng tɛm sayd ɛfɛkt dɛm fɔ ɛkspɛkt frɔm dɛn tritmɛnt ya? Wetin dɛn kin du fɔ mek dɛn nɔ bɔku?
• Aw lɔng tritmɛnt kin tek?
• Wetin yu kin tɛl mi bɔt mi prɔgnosis?
• A kin kɔntinyu fɔ du mi ɛvride (wok, os wok) we a de du tritmɛnt?
• Ɛni spɛshal tin dɛn de we a nid fɔ pe atɛnshɔn to bɔt di it we a de it ɛn ɛksesaiz?
• Wetin a go du fɔ ridyus di risk fɔ mek kansa kam bak?
• If a nid sɔpɔt savis ɔ advays, a kin gɛt riferal fɔ am?

I fayn fɔ rayt dɛn kwɛstyɔn ya ɛn aks dɛn, so dat yu nɔ go fɔgɛt ɛnitin.

I bɛtɛ fɔ bi HER2-positiv ɔ negatif?

Dis na kwɛstyɔn we bɔku pipul dɛn kin aks. Bɔt i at fɔ gi simpul ansa to dis, bikɔs di tru tin na dat i ‘dipen’ .

fכ egzampl, HER2-positiv brεst kεnsar dεm kin tεnd fכ gro fast εn bi mכr agresiv pas HER2-nεgεtiv kεnsar dεm. Bɔt, bɛnifit de fɔ dis. spεsifi k tεrapi dεm de we kin tכk to di HER2 protin dεm, fכ egzampl, Herceptin, Perjeta, εn dεn de rili ifektiv fכ HER2-positiv kεnsar dεm. dis tritmεnt dεm nכ de wok fכ HER2-nεgεtiv kεnsar dεm, biכs dεn kεnsar dεm de nכ gεt bכku HER2 protin fכ tכk.

na di כda say, if wan `HER2-nεgεtiv` kεnsar na `HR+` (hכmon rεsεptכr-positiv), dat na, `HR+/HER2-` tכp, den i gεt rili ifektiv כmon tεrapi dεm εn tεrapi dεm we dεn tכk bכt lεk `CDK4/6 inhibito dεm`. infakt, dεn kin kכnsidr `HR+/HER2-` brεst kεnsar fכ gεt di bεst prכgnosis bitwin di brεst kεnsar sכbtayp dεm we de naw.

bכt if di kεnsar na `HER2-nεgεtiv` (HR-) (hכmon rεsεpכta-nεgεtiv), dat na, tripl-nεgεtiv, i kin כltεm bi mכr agresiv pas כda kayn dεm, εn tritmεnt kin bi sכm mכr chεlεnj. Bɔt naw, kemotɛrapi, imyunotɛrapi, ɛn nyu tritmɛnt dɛn de we dɛn dɔn tɔk bɔt fɔ dat bak.

So, i nɔ pɔsibul fɔ se wan "bɛtɛ" ɔ "wɔs" pas di ɔda wan. Di tin we impɔtant pas ɔl na fɔ no di patikyula sɔbtayp fɔ yu kansa kɔrɛkt wan ɛn gɛt di tritmɛnt we go wok fayn pas ɔl we fit am.

Fɔ dɔn, a fɔ tɛl una... (Tek-Home Message)

We dɛn no se yu gɛt `HER2-negative` brɔst kansa, i nɔmal fɔ fil fred ɛn wɔri. Bɔt mɛmba se dis nɔto di ɛnd fɔ di wɔl. Sayns ɛn mɛrɛsin tɛknɔlɔji dɔn rili go bifo tide, ɛn bɔku fayn tritmɛnt dɛn de fɔ dis kayn kansa.

Di tin we impɔtant pas ɔl na:

• Fɔ mek dɛn no gud gud wan bɔt dis tin we de apin.
• Yu fɔ no ɔltɛm bɔt di chenj dɛn we de apin na yu bɔdi, mɔ na yu bɔdi.
• If yu gɛt ɛni dawt, go to dɔktɔ di rayt tɛm ɛn mek dɛn chɛk yu.
• Tɔk to yu dɔktɔ opin wan ɛn ɔnɛs wan, aks ɔl yu kwɛstyɔn dɛn, ɛn ɔndastand gud gud wan bɔt di tritmɛnt dɛn we yu go gɛt.

Mɛmba se nɔto yu wangren de du dis waka. Dɔktɔ dɛn de we gɛt sɛns, nɔs dɛn, yu famili, ɛn yu tayt padi dɛn we de de fɔ ɛp ɛn sɔpɔt yu. Kip yu fayn abit, fala yu dɔktɔ dɛn instrɔkshɔn dɛn gud gud wan, ɛn gɛt di sɔpɔt we yu nid, ɛn yu go mɔs ebul fɔ bia wit dis prɔblɛm fayn fayn wan ɛn wɛl. Mek yu strɔng!

` Brest kansa, HER2-negativ, kansa simptom, kansa tritmɛnt, uman dɛn wɛlbɔdi, ɔmon tɛrapi, tripl-negativ